NCT04823247View on ClinicalTrials.gov

Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study

CompletedOBSERVATIONAL
Enrollment

782

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Plaque Psoriasis
Interventions
DRUG

Tildrakizumab

As provided in real world clinical practice.

Trial Locations (1)

85354

Haut- und Laserzentrum Freising, Freising

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY